Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Thilo van Eimeren; Angelo Antonini; Daniela Berg; Nico Bohnen; Roberto Ceravolo; Alexander Drzezga; Günter U Höglinger; Makoto Higuchi; Stephane Lehericy; Simon Lewis; Oury Monchi; Peter Nestor; Matej Ondrus; Nicola Pavese; María Cecilia Peralta; Paola Piccini; José Ángel Pineda-Pardo; Irena Rektorová; María Rodríguez-Oroz; Axel Rominger; Klaus Seppi; A Jon Stoessl; Alessandro Tessitore; Stephane Thobois; Valtteri Kaasinen; Gregor Wenning; Hartwig R. Siebner; Antonio P Strafella; James B. Rowe

doi:10.1016/j.dadm.2019.01.011

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Thilo van Eimeren, Angelo Antonini, Daniela Berg, Nico Bohnen, Roberto Ceravolo, Alexander Drzezga, Günter U Höglinger, Makoto Higuchi, Stephane Lehericy, Simon Lewis, Oury Monchi, Peter Nestor, Matej Ondrus, Nicola Pavese, María Cecilia Peralta, Paola Piccini, José Ángel Pineda-Pardo, Irena Rektorová, María Rodríguez-Oroz, Axel RomingerKlaus Seppi, A Jon Stoessl, Alessandro Tessitore, Stephane Thobois, Valtteri Kaasinen, Gregor Wenning, Hartwig R. Siebner, Antonio P Strafella, James B. Rowe

Department of Clinical Medicine

16 Citations (Scopus)

Abstract

Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.

Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.

Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).

Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

Original language	English
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	11
Pages (from-to)	301-309
Number of pages	9
ISSN	2352-8729
DOIs	https://doi.org/10.1016/j.dadm.2019.01.011
Publication status	Published - Dec 2019

Access to Document

10.1016/j.dadm.2019.01.011Licence: CC BY-NC-ND

http://europepmc.org/articles/pmc6446052?pdf=renderLicence: CC BY-NC-ND

Cite this

van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M. C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., ... Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 11, 301-309. https://doi.org/10.1016/j.dadm.2019.01.011

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. / van Eimeren, Thilo; Antonini, Angelo; Berg, Daniela et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 12.2019, p. 301-309.

Research output: Contribution to journal › Journal article › Research › peer-review

van Eimeren, T, Antonini, A, Berg, D, Bohnen, N, Ceravolo, R, Drzezga, A, Höglinger, GU, Higuchi, M, Lehericy, S, Lewis, S, Monchi, O, Nestor, P, Ondrus, M, Pavese, N, Peralta, MC, Piccini, P, Pineda-Pardo, JÁ, Rektorová, I, Rodríguez-Oroz, M, Rominger, A, Seppi, K, Stoessl, AJ, Tessitore, A, Thobois, S, Kaasinen, V, Wenning, G, Siebner, HR, Strafella, AP & Rowe, JB 2019, 'Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 11, pp. 301-309. https://doi.org/10.1016/j.dadm.2019.01.011

@article{b02909f06c904ff7a020cffa9a911e80,

title = "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System",

abstract = "Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.",

author = "{van Eimeren}, Thilo and Angelo Antonini and Daniela Berg and Nico Bohnen and Roberto Ceravolo and Alexander Drzezga and H{\"o}glinger, {G{\"u}nter U} and Makoto Higuchi and Stephane Lehericy and Simon Lewis and Oury Monchi and Peter Nestor and Matej Ondrus and Nicola Pavese and Peralta, {Mar{\'i}a Cecilia} and Paola Piccini and Pineda-Pardo, {Jos{\'e} {\'A}ngel} and Irena Rektorov{\'a} and Mar{\'i}a Rodr{\'i}guez-Oroz and Axel Rominger and Klaus Seppi and Stoessl, {A Jon} and Alessandro Tessitore and Stephane Thobois and Valtteri Kaasinen and Gregor Wenning and Siebner, {Hartwig R.} and Strafella, {Antonio P} and Rowe, {James B.}",

year = "2019",

month = dec,

doi = "10.1016/j.dadm.2019.01.011",

language = "English",

volume = "11",

pages = "301--309",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier",

}

TY - JOUR

T1 - Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders

T2 - Proposal for a Neuroimaging Biomarker Utility System

AU - van Eimeren, Thilo

AU - Antonini, Angelo

AU - Berg, Daniela

AU - Bohnen, Nico

AU - Ceravolo, Roberto

AU - Drzezga, Alexander

AU - Höglinger, Günter U

AU - Higuchi, Makoto

AU - Lehericy, Stephane

AU - Lewis, Simon

AU - Monchi, Oury

AU - Nestor, Peter

AU - Ondrus, Matej

AU - Pavese, Nicola

AU - Peralta, María Cecilia

AU - Piccini, Paola

AU - Pineda-Pardo, José Ángel

AU - Rektorová, Irena

AU - Rodríguez-Oroz, María

AU - Rominger, Axel

AU - Seppi, Klaus

AU - Stoessl, A Jon

AU - Tessitore, Alessandro

AU - Thobois, Stephane

AU - Kaasinen, Valtteri

AU - Wenning, Gregor

AU - Siebner, Hartwig R.

AU - Strafella, Antonio P

AU - Rowe, James B.

PY - 2019/12

Y1 - 2019/12

N2 - Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

AB - Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

U2 - 10.1016/j.dadm.2019.01.011

DO - 10.1016/j.dadm.2019.01.011

M3 - Journal article

C2 - 30984816

SN - 2352-8729

VL - 11

SP - 301

EP - 309

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Abstract

Access to Document

Fingerprint

Cite this